Loading
A phase 2 trial of Pembrolizumab, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Teclison Ltd., now recruiting.
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC is a phase 2 interventional study registered as NCT04701476 by Teclison Ltd., with 110 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-03-31. Interventions recorded: TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill. Conditions listed: Colorectal Cancer; Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Teclison, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Regorafenib, Colorectal cancer.
Shares Trifluridine/tipiracil, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trifluridine/tipiracil, Colorectal cancer.
Shares Trifluridine/tipiracil, Regorafenib, Pembrolizumab, Colorectal cancer.
Shares Regorafenib, Immune checkpoint inhibitors.
Shares Regorafenib, Colorectal cancer.